- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Self-image.
Displaying page 1 of 1.
EudraCT Number: 2017-004066-10 | Sponsor Protocol Number: MVT-601-3103 | Start Date*: 2018-10-19 | |||||||||||
Sponsor Name:Myovant Sciences GmbH | |||||||||||||
Full Title: SPIRIT EXTENSION: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Co-Administered with Low-Dose Estradiol and Norethindrone Acetate in Wom... | |||||||||||||
Medical condition: Endometriosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) HU (Completed) BE (Completed) FI (Completed) SE (Completed) PL (Completed) CZ (Completed) BG (Completed) PT (Completed) IT (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-003941-42 | Sponsor Protocol Number: B4Z-SO-LY15 | Start Date*: 2005-02-11 |
Sponsor Name:Eli Lilly Sweden AB | ||
Full Title: A Randomised, Double Blind Placebo Controlled Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Swedish Children and ... | ||
Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD) is a common psychiatric disorder that has its onset in childhood, and that is estimated to occur in 3% to 6% of school-age children. ADHD is characte... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001588-19 | Sponsor Protocol Number: MVT-601-3101 | Start Date*: 2017-11-01 | |||||||||||
Sponsor Name:Myovant Sciences GmbH | |||||||||||||
Full Title: SPIRIT 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Ac... | |||||||||||||
Medical condition: Endometriosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Completed) HU (Completed) BE (Completed) PL (Completed) BG (Completed) PT (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001632-19 | Sponsor Protocol Number: MVT-601-3102 | Start Date*: 2017-12-01 | |||||||||||
Sponsor Name:Myovant Sciences GmbH | |||||||||||||
Full Title: SPIRIT 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Ac... | |||||||||||||
Medical condition: Endometriosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) CZ (Completed) PL (Completed) GB (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001984-21 | Sponsor Protocol Number: 3/013/13 | Start Date*: 2013-09-11 | |||||||||||
Sponsor Name:University of Aberdeen & NHS Grampian | |||||||||||||
Full Title: PRE-EMPT: Preventing Recurrence of Endometriosis by Means of long acting Protestogen Therapy | |||||||||||||
Medical condition: Endometriosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000716-30 | Sponsor Protocol Number: RGL-003-001 | Start Date*: 2020-09-10 | |||||||||||
Sponsor Name:Gedeon Richter Plc. | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter, proof-of-concept study to evaluate a combined oral contraceptive (COC) containing 30 µg ethinylestradiol and 150 µg levonorgestrel plus ... | |||||||||||||
Medical condition: Hypoactive sexual desire disorder (HSDD) secondary to combined oral contraception use. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) PL (Completed) CZ (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020956-69 | Sponsor Protocol Number: OX02 | Start Date*: 2011-02-23 | ||||||||||||||||
Sponsor Name:Universitätsklinikum Freiburg | ||||||||||||||||||
Full Title: Effekte von Oxytocin bei Patientinnen und Patienten mit Borderline-Persönlichkeitsstörung | ||||||||||||||||||
Medical condition: ICD-10 F60.3 Emotionally unstable personality disorder Two types may be distinguished: the impulsive type, characterized by emotional instability and lack of impulse control, and the borderline typ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
